Caas Capital Management LP Bio Atla, Inc. Transaction History

Caas Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $37,395 - $134,136	16,259 Added 25.47%	80,097 $214,000
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $401,541 - $702,856	63,838 New	63,838 $526,000
Q2 2021 Aug 16, 2021	SELL	$38.07 - $56.17 $2.66 Million - $3.93 Million	-70,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$31.02 - $35.16 $2.17 Million - $2.46 Million	70,000 New	70,000 $2.38 Million

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.